PIK3CA and breast cancer: The combination of taselisib, palbociclib, and fulvestrant was evaluated in patients, heavily pretreated with HR+ BC carrying PIK3CA‐mutant, with a therapy response rate in PIK3CA‐mutant in HR+/HER2− BC was 37.5% [350].